Acquired by LACROIX Group.
THERAtRAME develops and positions new therapeutics targeting tRNA epitranscriptomics in cancer.
QustomDot is developing cadmium-free quantum dots that are stable enough for advanced applications.
Axithra is developing new technology for accurate drug concentrations in blood.
